<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.91004</article-id><article-id pub-id-type="publisher-id">ACM-28461</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190100000_28787226.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  中低收入地区癌症筛查和早期诊断技术进展
  Advances in Cancer Screening and Early Diagnosis in Low- and Middle-Income Regions
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>祥松</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>亮</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>成</surname><given-names>亚农</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>扬州洪泉医院普外科，江苏 扬州</addr-line></aff><aff id="aff3"><addr-line>江苏大学医学院，江苏 镇江</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2019</year></pub-date><volume>09</volume><issue>01</issue><fpage>18</fpage><lpage>22</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    癌症是一类重要疾病，近年来发病率显著上升，并已成为阻碍发展中国家经济发展的重要因素之一。全民开展肿瘤疾病的早期筛查工作可以有效降低死亡率，极大地减轻公共卫生负担。由于各国经济发展水平不同，国民健康情况也不同，因此需要根据各国自身情况，选择合适的肿瘤筛查方法，开展全国性筛查工作。
    As an important disease, the incidence of cancer has increased significantly in recent years and has become one of the important factors hindering the economic development of developing countries. Early screening of cancer diseases in the whole population can effectively reduce the mortality rate and greatly reduce the burden of public health. Due to different economic development levels and national health conditions in different countries, it is necessary to select appropriate tumor screening methods and carry out nationwide screening according to their own conditions. 
  
 
</p></abstract><kwd-group><kwd>癌症，早期筛查，筛查方法, Cancer</kwd><kwd> Early Screening</kwd><kwd> Screening Methods</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>中低收入地区癌症筛查和早期诊断技术进展<sup> </sup></title><p>陈祥松<sup>1</sup>，吴亮<sup>2</sup>，成亚农<sup>1</sup></p><p><sup>1</sup>扬州洪泉医院普外科，江苏 扬州</p><p><sup>2</sup>江苏大学医学院，江苏 镇江</p><p><img src="//html.hanspub.org/file/4-1570784x1_hanspub.png" /></p><p>收稿日期：2018年12月19日；录用日期：2019年1月8日；发布日期：2019年1月15日</p><disp-formula id="hanspub.28461-formula18"><graphic xlink:href="//html.hanspub.org/file/4-1570784x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>癌症是一类重要疾病，近年来发病率显著上升，并已成为阻碍发展中国家经济发展的重要因素之一。全民开展肿瘤疾病的早期筛查工作可以有效降低死亡率，极大地减轻公共卫生负担。由于各国经济发展水平不同，国民健康情况也不同，因此需要根据各国自身情况，选择合适的肿瘤筛查方法，开展全国性筛查工作。</p><p>关键词 :癌症，早期筛查，筛查方法</p><disp-formula id="hanspub.28461-formula19"><graphic xlink:href="//html.hanspub.org/file/4-1570784x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1570784x7_hanspub.png" /> <img src="//html.hanspub.org/file/4-1570784x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 前言</title><p>癌症疾病治疗负担日益加重是近十年来对全球公共卫生影响最重要的事件。全球数据表明，2005年至2015年期间，新确诊的癌症病例总数增加了33%，其中4.1%的新增病例是非年龄相关因素发病的真实增加，其余新增病例可归因于人口增长(占12.6%)和人口老龄化(16.4%) [<xref ref-type="bibr" rid="hanspub.28461-ref1">1</xref>] 。全球中低收入地区癌症死亡率极高，2012年全球欠发达地区新发现癌症约800万例，其中530万例死亡 [<xref ref-type="bibr" rid="hanspub.28461-ref2">2</xref>] 。中低收入地区日益加重的癌症治疗负担对于中低收入国家财政是致命的，直接导致上述地区无法实现“于2030年将非传染性疾病死亡率降低三分之一”的可持续发展目标 [<xref ref-type="bibr" rid="hanspub.28461-ref3">3</xref>] 。大量研究表明，开展各种肿瘤的早期筛查工作，可以有效降低本地区肿瘤病死率，减轻医疗财政负担。现将近年来重要肿瘤在发达地区和欠发达地区早期筛查工作进行综述。</p></sec><sec id="s4"><title>2. 肿瘤筛查工作现状</title><sec id="s4_1"><title>2.1. 肿瘤疾病早期筛查的重要性</title><p>癌症种类繁多，但中低收入地区选择几种特定癌症并开展全国性早期筛查，对于减轻当地政府癌症治疗负担是非常有效的 [<xref ref-type="bibr" rid="hanspub.28461-ref4">4</xref>] 。这个特定癌症应该是当地具有高发病率或不断增加的发病率和/或导致显著死亡率的 [<xref ref-type="bibr" rid="hanspub.28461-ref5">5</xref>] 。目前全球发病率最高的五大癌症分别是乳腺癌、肺癌、结肠癌、前列腺癌和胃癌，而死亡率最高的依次是肺癌、结肠癌、胃癌、肝癌和乳腺癌。某些国家前列腺癌和结肠癌的发病率也呈明显上升趋势。</p></sec><sec id="s4_2"><title>2.2. 不同经济发展水平国家肿瘤筛查工作不平等</title><p>由于某些肿瘤早期筛查方法的不完善，目前发达国家已广泛开展早期系统性筛查肿瘤包括乳腺癌、宫颈癌和直肠癌。通过多年的运行，已取得令人满意的效果，显著降低了肿瘤患者的死亡率 [<xref ref-type="bibr" rid="hanspub.28461-ref6">6</xref>] 。但需要注意的是，在人群中广泛开展肿瘤筛查工作是一项极其耗费社会医疗资源的，并且需要一个高度组织化医疗卫生系统的复杂工程。中低收入国家的医疗卫生系统通常高度分散且人员和装备均不足，各部门之间缺乏必要的协调合作机制，直接阻碍了全国性肿瘤筛查工作的完成 [<xref ref-type="bibr" rid="hanspub.28461-ref7">7</xref>] 。因此，目前绝大多数中低收入国家要么尚未开展全民性质的癌症筛查工作，要么虽提出计划但无法落实到位。以宫颈癌为例，世界卫生组织(WHO)对全球57个国家的回顾性调查研究结果显示，宫颈癌筛查在全球范围内存在着巨大不平等，奥地利和卢森堡两国80%以上女性，在25岁至64岁之间，每3年最少接受一次子宫颈细胞涂片检查，而孟加拉国、埃塞俄比亚和缅甸等国上述检查比例不到1% [<xref ref-type="bibr" rid="hanspub.28461-ref8">8</xref>] 。</p><p>此外，中低收入国家的癌症筛查工作常因后续服务质量低下等问题而难以收到预期结果。许多年前，阿根廷、哥伦比亚、古巴、巴西和墨西哥等一些拉丁美洲国家推出了基于细胞的宫颈癌筛查项目，并成功地实现了对目标人群的合理高覆盖率。然后即使在实施了多年的筛查计划后，这些国家的宫颈癌死亡率也没有明显下降。从事筛选试验的检测人员经验和操作技能差，诊断评价质量体系不完整，以及受检人员由于各种原因不按规定要求受检或对检查结果不重视等诸多因素是造成上述结果的要原因 [<xref ref-type="bibr" rid="hanspub.28461-ref9">9</xref>] 。</p><p>公众意识有限、文化和宗教因素以难以均衡的卫生重点也是在中低收入国家开展癌症筛查的障碍。泰国公共卫生部在2004年开展宫颈癌筛查，建议30岁至60岁的女性每5年进行1次的宫颈刮片检查，并且这些服务都是完全免费提供的。但接受筛检的人数依然很低，不接受筛检的主要原因是她们不知道宫颈癌，不知道接受筛检对他们有何好处，或者检查过程感到尴尬 [<xref ref-type="bibr" rid="hanspub.28461-ref10">10</xref>] 。</p></sec><sec id="s4_3"><title>2.3. 不同国家需选择符合自身情况的肿瘤筛查方案</title><p>发达国家使用的筛选试验可能不适用于资源有限的发展中国家，这不仅是因为试验费用昂贵，而且还因为缺乏训练有素的人员和实验室基础设施。例如，由于缺乏训练有素的放射科医师，大多数中等收入国家不可能实施乳腺癌乳房X线照相术筛查；由于缺乏合格实验室和训练有素的细细胞病理学医师家，巴氏涂片细胞学检查的敏感度可能非常低 [<xref ref-type="bibr" rid="hanspub.28461-ref11">11</xref>] 。</p></sec></sec><sec id="s5"><title>3. 重要肿瘤筛查工作进展</title><sec id="s5_1"><title>3.1. 宫颈癌筛查工作</title><p>目前80%的宫颈癌病例存在于发展中国家，主要原因是上述国家缺乏有效的筛查项目。而西方发达国家通常的巴氏涂片细胞筛查模式在发展中国家是难以开展的。巴氏涂片法敏感度仅为57% (95%可信区间为38%~76%)，并且需要多次重复检查也保证可靠性。开展巴氏涂片法检查需要训练有素的细胞病理学家，上述各种原因都阻碍了巴氏涂片法在中低收入国家的开展 [<xref ref-type="bibr" rid="hanspub.28461-ref12">12</xref>] 。</p><p>乙酸目视检查法(VIA)是适宜在发展中国家开展，并可以替代巴氏涂片法 [<xref ref-type="bibr" rid="hanspub.28461-ref13">13</xref>] 。VIA检查的主要优点是，当由训练有素的检查人员操作时可理想的灵敏度。其操作简单，成本低，检查结果可立即获得，方便临床医生开展进一步检查和治疗。整个过程可以将“筛选和治疗”同时进行，具有很高的可接受性 [<xref ref-type="bibr" rid="hanspub.28461-ref14">14</xref>] 。但该方法的主要缺点是它的主观性和较低的专一性。检测者需要首先进行专业化培训，并定期接受监督和再培训，以确保测试的高质量。</p></sec><sec id="s5_2"><title>3.2. 乳腺癌筛查工作</title><p>近年来乳腺癌在全球范围内呈现迅速上升趋势，且在发展中国家的增幅更为迅速。2005年至2015年期间，全球乳腺癌发病率上升了26%。而发达国家通过开展乳腺钼靶技术筛查50岁~64岁之间女性可有效降低乳腺癌死亡率40%。大量发达国家乳腺癌研究结果表明，其死亡率下降的主要原因是系统筛查的开展和多模式治疗相结合的结果 [<xref ref-type="bibr" rid="hanspub.28461-ref15">15</xref>] 。但乳腺钼靶技术筛查的开展需要在基础设施、人力资源和质量保证方面进行大量投资，这已超出了大多数中等收入国家的能力。因此世卫组织建议乳腺钼靶技术仅适用于卫生系统组织良好的高中等收入国家 [<xref ref-type="bibr" rid="hanspub.28461-ref16">16</xref>] 。</p><p>临床乳腺检查(clinical breast examination, CBE)作为乳腺钼靶技术的一种替代方法，其有效性已在大量随机试验中得到证实，但目前没有研究结果能够证明CBE筛查可以降低死亡率 [<xref ref-type="bibr" rid="hanspub.28461-ref17">17</xref>] 。即便如此，CBE在孟加拉国、加纳、印度和摩洛哥等国仍被用作乳腺癌筛查试验。鉴于乳腺癌的低龄化趋势明显，上述国家的CBE筛查通常从较早的年龄段人群开始。但CBE技术对乳腺癌的检出率仅为1.0/1000，明显低于乳腺钼靶技术 [<xref ref-type="bibr" rid="hanspub.28461-ref18">18</xref>] 。</p><p>不管各种筛查技术的检出率如何，对于中低收入国家来说最重要的是确保在早期阶段发现疾病，并及时采取合适治疗措施 [<xref ref-type="bibr" rid="hanspub.28461-ref19">19</xref>] 。对于乳腺癌患者，早期发现并治疗的存活率可超过90%。但大多数发展中国家，如撒哈拉以南非洲及其他低收入国家，近75%的乳腺癌患者被发现时已处于晚期 [<xref ref-type="bibr" rid="hanspub.28461-ref20">20</xref>] 。确保早期诊断的关键是培养健康者保健意识，了解乳腺癌的早期症状，并定期去医院进行CBE检查。</p></sec><sec id="s5_3"><title>3.3. 结直肠癌筛查工作</title><p>结直肠癌(colorectal cancer, CRC)发病率近年为也呈上升趋势，尤其是男性患者，其中社会经济发展指数(socio-economic development index, SDI)较低的国家结直肠癌发病率增长尤为迅速 [<xref ref-type="bibr" rid="hanspub.28461-ref21">21</xref>] 。然而大多数中低收入国家目前结直肠癌疾病负担仍处于较低水平，因此进行系统化筛查大量人群的国家并不多。但巴西和一些中东地区国家(如摩洛哥和伊朗等)已开始了结直肠癌的筛查工作，主要采用粪便免疫化学法进行筛查。该方法在发达国家广泛采用，同样适用于发展中国家 [<xref ref-type="bibr" rid="hanspub.28461-ref22">22</xref>] 。粪便免疫化学法简单、客观且易学，受试者不需要任何饮食限制，非常适合于现场检查。粪便免疫化学法筛查阳性受试者需要进一步通过结肠镜检查，可以极大地节省开展结肠镜筛查花费 [<xref ref-type="bibr" rid="hanspub.28461-ref23">23</xref>] 。</p></sec></sec><sec id="s6"><title>4. 展望</title><p>癌症是所有低收入国家卫生防控的重点，开展有计划筛查以尽早发现癌症是癌症防控规划的重要组成部分。各国家和地区应结合当地癌症发病的特点，以及国家财政情况和医疗体系完整度，合理制定适合本地区的肿瘤预防、筛查、早期诊断策略，谨慎选择筛选方法和干预措施。只有建立和完善高质量和及时的癌症诊断和治疗服务机制，才能提高癌症患者生存率，并在一定程度上减轻了中低收入国家国民享受公共卫生服务不平等现象，促进当地经济水平发展。</p></sec><sec id="s7"><title>文章引用</title><p>陈祥松,吴 亮,成亚农. 中低收入地区癌症筛查和早期诊断技术进展Advances in Cancer Screening and Early Diagnosis in Low- and Middle-Income Regions[J]. 临床医学进展, 2019, 09(01): 18-22. https://doi.org/10.12677/ACM.2019.91004</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28461-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Independent UK Panel on Breast Cancer Screening (2012) The Benefits and Harms of Breast Cancer Screening: An Independent Review. Lancet, 380, 1778-1786. &lt;br&gt;https://doi.org/10.1016/S0140-6736(12)61611-0</mixed-citation></ref><ref id="hanspub.28461-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Swan, J., Breen, N., Coates, R.J., et al. (2003) Progress in Cancer Screening Practices in the United States: Results from the 2000 National Health Interview Survey. Cancer, 97, 1528-1540. &lt;br&gt;https://doi.org/10.1002/cncr.11208</mixed-citation></ref><ref id="hanspub.28461-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tabar, L., Yen, M.F., Vitak, B., et al. (2003) Mammography Service Screening and Mortality in Breast Cancer Patients: 20-Year Follow-Up before and after Introduction of Screening. Lancet, 361, 1405-1410.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(03)13143-1</mixed-citation></ref><ref id="hanspub.28461-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Leung, W.K., Wu, M.S., Kakugawa, Y., et al. (2008) Screening for Gastric Cancer in Asia: Current Evidence and Practice. The Lancet Oncology, 9, 279-287. &lt;br&gt;https://doi.org/10.1016/S1470-2045(08)70072-X</mixed-citation></ref><ref id="hanspub.28461-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ahn, H.S., Kim, H.J. and Welch, H.G. (2014) Korea’s Thyroid-Cancer “Epidemic”—Screening and Overdiagnosis. The New England Journal of Medicine, 371, 1765-1767. &lt;br&gt;https://doi.org/10.1056/NEJMp1409841</mixed-citation></ref><ref id="hanspub.28461-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Peto, J., Gilham, C., Fletcher, O., et al. (2004) The Cervical Cancer Epidemic that Screening Has Prevented in the UK. Lancet, 364, 249-256. &lt;br&gt;https://doi.org/10.1016/S0140-6736(04)16674-9</mixed-citation></ref><ref id="hanspub.28461-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tashiro, A., Sano, M., Kinameri, K., et al. (2006) Comparing Mass Screening Techniques for Gastric Cancer in Japan. World Journal of Gastroenterology, 12, 4873-4874.</mixed-citation></ref><ref id="hanspub.28461-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ronco, G., Giorgi-Rossi, P., Carozzi, F., et al. (2010) Efficacy of Human Papillomavirus Testing for the Detection of Invasive Cervical Cancers and Cervical Intraepithelial Neoplasia: A Randomised Controlled Trial. The Lancet Oncology, 11, 249-257. &lt;br&gt;https://doi.org/10.1016/S1470-2045(09)70360-2</mixed-citation></ref><ref id="hanspub.28461-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Pourasad-Shahrak, S., Salehi-Pourmehr, H., Mostafa-Garebaghi, P., et al. (2015) Comparing the Results of Pap Smear and Direct Visual In-spection (DVI) with 5% Acetic Acid in Cervical Cancer Screening. Nigerian Medical Journal, 56, 35-38. &lt;br&gt;https://doi.org/10.4103/0300-1652.149168</mixed-citation></ref><ref id="hanspub.28461-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Gakidou, E., Nordhagen, S. and Obermeyer, Z. (2008) Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and Large Inequalities. PLOS Medicine, 5, e132. &lt;br&gt;https://doi.org/10.1371/journal.pmed.0050132</mixed-citation></ref><ref id="hanspub.28461-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Katapodi, M.C., Lee, K.A., Facione, N.C., et al. (2004) Pre-dictors of Perceived Breast Cancer Risk and the Relation between Perceived Risk and Breast Cancer Screening: A Me-ta-Analytic Review. Preventive Medicine, 38, 388-402.  
&lt;br&gt;https://doi.org/10.1016/j.ypmed.2003.11.012</mixed-citation></ref><ref id="hanspub.28461-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Curry, S.J., Krist, A.H., Owens, D.K., et al. (2018) Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 320, 674-686. &lt;br&gt;https://doi.org/10.1001/jama.2018.10897</mixed-citation></ref><ref id="hanspub.28461-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bibbins-Domingo, K., Grossman, D.C., Curry, S.J., et al. (2017) Screening for Gynecologic Conditions with Pelvic Examination: US Preventive Services Task Force Recommendation Statement. JAMA, 317, 947-953.  
&lt;br&gt;https://doi.org/10.1001/jama.2017.0807</mixed-citation></ref><ref id="hanspub.28461-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sherris, J., Wittet, S., Kleine, A., et al. (2009) Evidence-Based, Al-ternative Cervical Cancer Screening Approaches in Low-Resource Settings. International Perspectives on Sexual and Reproductive Health, 35, 147-154.  
&lt;br&gt;https://doi.org/10.1363/3514709</mixed-citation></ref><ref id="hanspub.28461-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Siu, A.L., US Preventive Services Task Force (2009) Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 151, 716-726.</mixed-citation></ref><ref id="hanspub.28461-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Voogd, A.C. (2013) The Impact of Mammography Screening on Breast Cancer Incidence. Journal of Comparative Effectiveness Research, 2, 113-116. &lt;br&gt;https://doi.org/10.2217/cer.13.3</mixed-citation></ref><ref id="hanspub.28461-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Chiarelli, A.M., Majpruz, V., Brown, P., et al. (2009) The Contribution of Clinical Breast Examination to the Accuracy of Breast Screening. JNCI: Journal of the National Cancer Institute, 101, 1236-1243.  
&lt;br&gt;https://doi.org/10.1093/jnci/djp241</mixed-citation></ref><ref id="hanspub.28461-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Andresen, E.M., Peterson-Besse, J.J., Krahn, G.L., et al. (2013) Pap, Mammography, and Clinical Breast Examination Screening among Women with Disabilities: A Systematic Review. Women’s Health Issues, 23, e205-e214.  
&lt;br&gt;https://doi.org/10.1016/j.whi.2013.04.002</mixed-citation></ref><ref id="hanspub.28461-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Tonelli, M., Connor, G.S., Joffres, M., et al. (2011) Recommen-dations on Screening for Breast Cancer in Average-Risk Women Aged 40 - 74 Years. CMAJ, 183, 1991-2001. &lt;br&gt;https://doi.org/10.1503/cmaj.110334</mixed-citation></ref><ref id="hanspub.28461-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Sankaranarayanan, R., Sauvaget, C., Ramadas, K., et al. (2011) Clinical Trials of Cancer Screening in the Developing World and Their Impact on Cancer Healthcare. Annals of Oncology, 22, i20-i28.  
&lt;br&gt;https://doi.org/10.1093/annonc/mdr422</mixed-citation></ref><ref id="hanspub.28461-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Walsh, J.M. and Terdiman, J.P. (2003) Colorectal Cancer Screening: Scientific Review. JAMA, 289, 1288-1296.  
&lt;br&gt;https://doi.org/10.1001/jama.289.10.1288</mixed-citation></ref><ref id="hanspub.28461-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Brenner, H. and Chen, H. (2017) Fecal Occult Blood versus DNA Testing: Indirect Comparison in a Colorectal Cancer Screening Population. Clinical Epidemiology, 9, 377-384. &lt;br&gt;https://doi.org/10.2147/CLEP.S136565</mixed-citation></ref><ref id="hanspub.28461-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Hol, L., van Leerdam, M.E., van Ballegooijen, M., et al. (2010) Screening for Colorectal Cancer: Randomised Trial Comparing Guaiac-Based and Immunochemical Faecal Occult Blood Testing and Flexible Sigmoidoscopy. Gut, 59, 62-68. &lt;br&gt;https://doi.org/10.1136/gut.2009.177089</mixed-citation></ref></ref-list></back></article>